Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
editorial
. 1992;19(2):73–78.

Should All Patients with Risk Factors for Ischemic Heart Disease Receive Aspirin?

James T Willerson 1,2,3, Susan D Mueller 1,2,3, James J Ferguson 1,2,3
PMCID: PMC326255  PMID: 15227418

Abstract

Unstable angina appears to be caused by relatively brief, repetitive episodes of myocardial oxygen impairment secondary to platelet aggregation and dynamic vasoconstriction at sites of coronary stenosis and endothelial injury. With chronic endothelial injury, the accumulation of thromboxane A2, serotonin, and other mediators may contribute to platelet aggregation and dynamic vasoconstriction. Aspirin acetylates the platelet enzyme, cyclooxygenase, thereby inhibiting the formation of thromboxane A2. In certain patients with unstable angina, 1 to 4 aspirin tablets per day has proved beneficial in reducing the risk of myocardial infarction and death. Moreover, combining aspirin with a selected thrombolytic agent, such as streptokinase, appears to potentiate thrombolysis and further reduce mortality. Aspirin's toxicity to the gastrointestinal tract and its tendency to decrease vascular concentrations of prostacyclin, a local endothelial factor that hinders thrombogenesis and promotes endogenous vasodilation, are concerns when used in long-term treatment; for this reason, we do not recommend aspirin therapy for every patient with an acute coronary syndrome. We do, however, advocate such therapy for those with unstable angina and, in combination with selected thrombolytic interventions, for those with acute Q-wave myocardial infarctions in whom aspirin is not contraindicated. (Texas Heart Institute Journal 1992; 19:73-8)

Keywords: Angina pectoris

Keywords: aspirin, therapeutic use

Keywords: blood platelets

Keywords: coronary circulation

Keywords: coronary disease

Keywords: endothelium, vascular

Keywords: myocardial infarction

Keywords: platelèt aggregation

Keywords: thrombosis

Keywords: vasoconstriction

Full text

PDF
73

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton J. H., Benedict C. R., Fitzgerald C., Raheja S., Taylor A., Campbell W. B., Buja L. M., Willerson J. T. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986 Mar;73(3):572–578. doi: 10.1161/01.cir.73.3.572. [DOI] [PubMed] [Google Scholar]
  2. Ashton J. H., Golino P., McNatt J. M., Buja L. M., Willerson J. T. Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. J Am Coll Cardiol. 1989 Mar 1;13(3):755–763. doi: 10.1016/0735-1097(89)90622-0. [DOI] [PubMed] [Google Scholar]
  3. Ashton J. H., Ogletree M. L., Michel I. M., Golino P., McNatt J. M., Taylor A. L., Raheja S., Schmitz J., Buja L. M., Campbell W. B. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987 Oct;76(4):952–959. doi: 10.1161/01.cir.76.4.952. [DOI] [PubMed] [Google Scholar]
  4. Ashton J. H., Schmitz J. M., Campbell W. B., Ogletree M. L., Raheja S., Taylor A. L., Fitzgerald C., Buja L. M., Willerson J. T. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists. Circ Res. 1986 Nov;59(5):568–578. doi: 10.1161/01.res.59.5.568. [DOI] [PubMed] [Google Scholar]
  5. Buja L. M., Willerson J. T. Clinicopathologic correlates of acute ischemic heart disease syndromes. Am J Cardiol. 1981 Feb;47(2):343–356. doi: 10.1016/0002-9149(81)90407-0. [DOI] [PubMed] [Google Scholar]
  6. Bush L. R., Campbell W. B., Buja L. M., Tilton G. D., Willerson J. T. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984 Jun;69(6):1161–1170. doi: 10.1161/01.cir.69.6.1161. [DOI] [PubMed] [Google Scholar]
  7. Bush L. R., Campbell W. B., Kern K., Tilton G. D., Apprill P., Ashton J., Schmitz J., Buja L. M., Willerson J. T. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res. 1984 Nov;55(5):642–652. doi: 10.1161/01.res.55.5.642. [DOI] [PubMed] [Google Scholar]
  8. Cairns J. A., Gent M., Singer J., Finnie K. J., Froggatt G. M., Holder D. A., Jablonsky G., Kostuk W. J., Melendez L. J., Myers M. G. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369–1375. doi: 10.1056/NEJM198511283132201. [DOI] [PubMed] [Google Scholar]
  9. Coller B. S., Folts J. D., Smith S. R., Scudder L. E., Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989 Dec;80(6):1766–1774. doi: 10.1161/01.cir.80.6.1766. [DOI] [PubMed] [Google Scholar]
  10. Davies M. J., Thomas A. C. Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985 Apr;53(4):363–373. doi: 10.1136/hrt.53.4.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Eidt J. F., Ashton J., Golino P., McNatt J., Buja L. M., Willerson J. T. Thromboxane A2 and serotonin mediate coronary blood flow reductions in unsedated dogs. Am J Physiol. 1989 Sep;257(3 Pt 2):H873–H882. doi: 10.1152/ajpheart.1989.257.3.H873. [DOI] [PubMed] [Google Scholar]
  12. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J. 1983 Aug;50(2):127–134. doi: 10.1136/hrt.50.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fitzgerald D. J., Roy L., Catella F., FitzGerald G. A. Platelet activation in unstable coronary disease. N Engl J Med. 1986 Oct 16;315(16):983–989. doi: 10.1056/NEJM198610163151602. [DOI] [PubMed] [Google Scholar]
  14. Folts J. D., Rowe G. G. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res. 1988 May 15;50(4):507–516. doi: 10.1016/0049-3848(88)90199-5. [DOI] [PubMed] [Google Scholar]
  15. Golino P., Ashton J. H., Buja L. M., Rosolowsky M., Taylor A. L., McNatt J., Campbell W. B., Willerson J. T. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. Circulation. 1989 Jan;79(1):154–166. doi: 10.1161/01.cir.79.1.154. [DOI] [PubMed] [Google Scholar]
  16. Golino P., Ashton J. H., Glas-Greenwalt P., McNatt J., Buja L. M., Willerson J. T. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation. 1988 Mar;77(3):678–684. doi: 10.1161/01.cir.77.3.678. [DOI] [PubMed] [Google Scholar]
  17. Golino P., Ashton J. H., McNatt J., Glas-Greenwalt P., Yao S. K., O'Brien R. A., Buja L. M., Willerson J. T. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation. 1989 Apr;79(4):911–919. doi: 10.1161/01.cir.79.4.911. [DOI] [PubMed] [Google Scholar]
  18. Golino P., Buja L. M., Ashton J. H., Kulkarni P., Taylor A., Willerson J. T. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation. 1988 Sep;78(3):701–711. doi: 10.1161/01.cir.78.3.701. [DOI] [PubMed] [Google Scholar]
  19. Hamm C. W., Lorenz R. L., Bleifeld W., Kupper W., Wober W., Weber P. C. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol. 1987 Nov;10(5):998–1006. doi: 10.1016/s0735-1097(87)80336-4. [DOI] [PubMed] [Google Scholar]
  20. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  21. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  22. Ludmer P. L., Selwyn A. P., Shook T. L., Wayne R. R., Mudge G. H., Alexander R. W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986 Oct 23;315(17):1046–1051. doi: 10.1056/NEJM198610233151702. [DOI] [PubMed] [Google Scholar]
  23. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. doi: 10.1136/bmj.296.6618.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rubanyl G. M., Frye R. L., Holmes D. R., Jr, Vanhoutte P. M. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol. 1987 Jun;9(6):1243–1249. doi: 10.1016/s0735-1097(87)80462-x. [DOI] [PubMed] [Google Scholar]
  25. Schmitz J. M., Apprill P. G., Buja L. M., Willerson J. T., Campbell W. B. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia. Circ Res. 1985 Aug;57(2):223–231. doi: 10.1161/01.res.57.2.223. [DOI] [PubMed] [Google Scholar]
  26. Sherman C. T., Litvack F., Grundfest W., Lee M., Hickey A., Chaux A., Kass R., Blanche C., Matloff J., Morgenstern L. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986 Oct 9;315(15):913–919. doi: 10.1056/NEJM198610093151501. [DOI] [PubMed] [Google Scholar]
  27. Tschopp T. B. Aspirin inhibits platelet aggregation on, but not adhesion to, collagen fibrils: an assessment of platelet adhesion and deposited platelet mass by morphometry and 51Cr-labeling. Thromb Res. 1977 Nov;11(5):619–632. doi: 10.1016/0049-3848(77)90020-2. [DOI] [PubMed] [Google Scholar]
  28. Willerson J. T., Campbell W. B., Winniford M. D., Schmitz J., Apprill P., Firth B. G., Ashton J., Smitherman T., Bush L., Buja L. M. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. Am J Cardiol. 1984 Dec 1;54(10):1349–1354. doi: 10.1016/s0002-9149(84)80095-8. [DOI] [PubMed] [Google Scholar]
  29. Willerson J. T., Golino P., Eidt J., Campbell W. B., Buja L. M. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation. 1989 Jul;80(1):198–205. doi: 10.1161/01.cir.80.1.198. [DOI] [PubMed] [Google Scholar]
  30. Willerson J. T., Hillis L. D., Winniford M., Buja L. M. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol. 1986 Jul;8(1):245–250. doi: 10.1016/s0735-1097(86)80121-8. [DOI] [PubMed] [Google Scholar]
  31. Yao S. K., Benedict C. R., Rosolowsky M., McNatt J., Falinska B., Campbell W. B., Buja L. M., Willerson J. T. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. J Mol Cell Cardiol. 1991 Apr;23(4):473–482. doi: 10.1016/0022-2828(91)90171-h. [DOI] [PubMed] [Google Scholar]
  32. van den Berg E. K., Schmitz J. M., Benedict C. R., Malloy C. R., Willerson J. T., Dehmer G. J. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation. 1989 Jan;79(1):116–124. doi: 10.1161/01.cir.79.1.116. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES